TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Simcere Pharmaceutical Group Limited ( (HK:2096) ) is now available.
Simcere Pharmaceutical Group Limited announced the approval of its new drug, QUVIVIQ®, for marketing in China by the National Medical Products Administration. Developed jointly with Idorsia Pharmaceuticals, QUVIVIQ® is a dual orexin receptor antagonist designed to treat insomnia in adults. This approval marks a significant milestone for Simcere, enhancing its market presence in China and potentially improving treatment options for insomnia patients. The drug has already been approved in several other countries, indicating its growing international acceptance and potential impact on the insomnia treatment market.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. It focuses on the development and marketing of innovative drugs, particularly in collaboration with other pharmaceutical entities, to address various medical needs.
Average Trading Volume: 14,546,822
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.88B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.